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Posaconazole oral suspension is widely used for antifungal prophylaxis and treatment in immunocompromised patients, with
highly variable pharmacokinetics reported in patients due to inconsistent oral absorption. This study aimed to characterize the
pharmacokinetics of posaconazole in adults and investigate factors that influence posaconazole pharmacokinetics byusing a
population pharmacokinetic approach. Nonlinear mixed-effects modeling was undertaken for two posaconazole studies in pa-
tients and healthy volunteers. The influences of demographic and clinical characteristics, such as mucositis, diarrhea, and drug-
drug interactions, on posaconazole pharmacokinetics were investigated using a stepwise forward inclusion/backwards deletion
procedure. A total of 905 posaconazole concentrationmeasurements from 102 participants were analyzed. A one-compartment
pharmacokinetic model with first-order oral absorption with lag time and first-order elimination best described posaconazole
pharmacokinetics. Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy
volunteers. Coadministration of proton pump inhibitors (PPIs) or metoclopramide, as well as the occurrence of mucositis or
diarrhea, reduced posaconazole relative bioavailability by 45%, 35%, 58%, and 45%, respectively, whereas concomitant inges-
tion of a nutritional supplement significantly increased bioavailability (129% relative increase). Coadministration of rifampin or
phenytoin increased apparent posaconazole clearance by more than 600%, with a smaller increase observed with fosamprenavir
(34%). Participant age, weight, or sex did not significantly affect posaconazole pharmacokinetics. Posaconazole absorption was
reduced by a range of commonly coadministered medicines and clinical complications, such as mucositis and diarrhea. Avoid-
ance of PPIs andmetoclopramide and administration with food or a nutritional supplement are effective strategies to increase
posaconazole absorption.
Posaconazole is a triazole antifungal agent with a broad anti-fungal spectrum and is widely used for antifungal prophylaxis
and treatment in immunocompromised patients (1, 2). Signifi-
cant pharmacokinetic variability has been reported in patients ad-
ministered posaconazole, with dose-dependent, saturable oral ab-
sorption and a large food effect contributing to this variability (3,
4). In addition, a range of drug-drug interactions and conditions
affecting the gastrointestinal tract are known to influence po-
saconazole absorption (5–8), adding to the inconsistent bioavail-
ability often associated with posaconazole (9).
Despite these pharmacokinetic challenges, which may have
been expected to compromise efficacy, posaconazole prophylaxis
was associated with few cases of breakthrough invasive fungal in-
fections (IFIs) in two pivotal randomized, controlled trials (1, 10).
Exposure-response relationships with posaconazole and the value
of therapeutic drug monitoring (TDM) have been widely debated
(9, 11, 12), although increasing evidence supports the role of TDM
in managing pharmacokinetic variability and optimizing po-
saconazole treatment (6, 9, 11, 13–15). Although an absolute tar-
get concentration has not yet been clearly defined for the preven-
tion of breakthrough fungal infection, recent reports suggest a
target posaconazole concentration of 0.7 mg/liter (9, 11). A
number of studies have reported that 50% of patients achieve
posaconazole exposure above this target (6, 7, 16–19). Knowledge
on the factors that cause this pharmacokinetic variability is of the
greatest importance to prevent suboptimal exposure and subse-
quent failure of prophylaxis.
Using pharmacokinetic studies undertaken in healthy volun-
teers and patients, this study aimed to characterize the pharmaco-
kinetics of posaconazole oral suspension in adults and evaluate the
influence of demographic and clinical covariates on posaconazole
exposure by using a population pharmacokinetic approach to in-
form the optimal use of posaconazole in clinical practice. A tablet
formulation of posaconazole with improved oral bioavailability
has recently been approved in the United States (20); this analysis
focuses on the oral suspension formulation of posaconazole,
which is widely used and remains available worldwide.
MATERIALS AND METHODS
Pharmacokinetic data and participants. Pharmacokinetic, demo-
graphic, and relevant clinical data from two posaconazole studies in
healthy volunteers and in patients receiving a posaconazole oral suspen-
sion for the prophylaxis or treatment of fungal infections were available
for analysis (6, 21). Information on study design, population, pharmaco-
kinetic data, and participant demographics is included in Table 1. Further
details on these studies have been described previously (6, 21).
Population pharmacokinetic modeling. The pharmacokinetic data
were analyzed using nonlinear mixed-effects modeling with NONMEM
7.2 (Globomax LLC, Hanover, MD). The gfortran compiler (version 4.6)
was used with NONMEM within Pirana (version 2.8; Pirana Software)
and Perl-Speaks-NONMEM (version 3.5.3; http://psn.sourceforge.net/)
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was used for model execution. Data visualization was performed with R
(version 2.15.2; http://www.r-project.org/), Xpose (version 4.4; http:
//xpose.sourceforge.net/), andMicrosoft Excel 2010. The first-order con-
ditional estimation method with interaction was used throughout model
development.
Structural model and variability. The structural pharmacokinetic
model was developed using a stepwise approach. The base pharmacoki-
netic model was initially developed using the richly sampled concentra-
tion-time data (study 1, healthy volunteer data [21]), with sparsely sam-
pled data (study 2, patient data [6]), and then incorporated into themodel
with appropriate goodness-of-fit testing.
Discrimination between nested models was made by comparison of
the objective function value (OFV). A significance level of P 0.05, cor-
responding to a decrease of 3.84 in the OFV, was considered statistically
significant. In addition, the following plots were used for diagnostic pur-
poses: (i) observed versus individually predicted values; (ii) observed ver-
sus population-predicted values; (iii) time versus weighted residuals; (iv)
population predictions versus weighted residuals.
Pharmacokinetic models incorporating either one or two compart-
ments with linear elimination were investigated. Due to the erratic and
incomplete absorption associated with the posaconazole suspension (5,
9), a range of approaches were investigated to describe posaconazole ab-
sorption. These included first-order absorption (with and without ab-
sorption lag time), dose-dependent saturable absorption, and a multiple-
dose transit compartment model (22). Interindividual variability (IIV)
and interoccasion variability (IOV; also termed intraindividual variabil-
ity) in posaconazole pharmacokinetic parameters were evaluated by using
exponential error models. Proportional, additive, and combined additive
and proportional residual error models were evaluated.
Covariatemodel.Participant-specific covariates, such as bodyweight,
age, and sex, and clinical covariates, such as mucositis or diarrhea on the
day of posaconazole concentration sampling and administration of po-
saconazole suspension via a nasogastric (NG) tube, and potential drug-
drug and food-drug interactions, including concomitant proton pump
inhibitors (PPIs), metoclopramide, phenytoin, or rifampin, a nutritional
supplement, ranitidine, and fosamprenavir, were investigated. Only bio-
logically plausible parameter-covariate relationships were explored. Con-
tinuous covariates were examined in the first instance by using linear
parameter-covariate relations, with the exception of the effect of body
weight on apparent clearance (CL), which was also tested using allometric
scaling with an exponent of 0.75. Categorical covariates were parameter-
ized as a multiplicative effect on the associated structural parameter.
Covariate testing was undertaken using a stepwise forward inclusion
and backwards deletion procedure. During forward inclusion, all param-
eter-covariate relationswere initially investigated, with the covariate caus-
ing the largest reduction in the NONMEM-derived OFV (i.e., 2-log
likelihood) retained in the model for the next step, until no significant
parameter-covariate relationships remained. During backwards deletion,
all significant parameter-covariate relationships were reevaluated in the
model obtained from the forward inclusion procedure, with covariates
not meeting significance criteria being removed from themodel in a step-
wisemanner. A P value of0.005 (decrease inOFV of7.88) was used to
evaluate covariates during forward inclusion, while the backward deletion
procedure used a stricter criterion (increase in OFV of10.83 upon de-
letion; P 0.001).
Model validation. Prediction- and variability-corrected visual predic-
tive checks (pvcVPCs) were used for model validation (23). Similar to
visual predictive checks, pvcVPCs allow a graphical assessment of the
predictive performance of a model by comparing model simulations and
observed data in terms of central trend and variability but differ in that
both model simulations and observed data are normalized to correct for
differences arising from independent variables (e.g., differences in dose,
time, or covariates) as well as the typical population variability in each bin
(23). A total of 1,000 simulated data sets of individuals from the original
data set were compared with prediction- and variability-corrected ob-
served concentrations. In addition, a nonparametric bootstrap procedure
(200 data sets) was used to determine the uncertainty of parameter esti-
mates in the final model.
Effects of covariates on posaconazole exposure. Simulations from
the final pharmacokinetic model were performed to quantitate the influ-
ence of significant covariates on posaconazole exposure. For each signif-
icant covariate effect, 1,000 patient simulations were performed to predict
steady-state posaconazole trough concentrations on day 10 of treatment
following the recommended posaconazole oral suspension dosing regi-
men for antifungal prophylaxis (posaconazole suspension of 200 mg,
three times daily). Predicted trough posaconazole concentrations with
and without each covariate were compared with the recommended po-
saconazole target concentration for antifungal prophylaxis (0.7 mg/li-
ter) (9).
RESULTS
Model development and validation. A total of 905 posaconazole
concentration measurements (study 1, 440 measurements; study
2, 465 measurements) from a total of 102 participants were in-
cluded in this analysis. A one-compartment pharmacokinetic
model with first-order oral absorptionwith an absorption lag time
and first-order elimination best described the pharmacokinetic
data set. Models incorporating dose-dependent saturable absorp-
tion or a multiple-dose transit compartment model were not se-
lected, because they did not significantly improve the goodness of
fit of the structural pharmacokinetic model. Interoccasion vari-
ability in relative posaconazole bioavailability was associated with
significantly improved goodness of fit andwas retained in the final
model. A proportional residual error model, stratified by study,
was used. Goodness-of-fit plots and pvcVPCs used throughout
model development indicated an acceptablemodel fit (Fig. 1). The
pvcVPCs of the final model (Fig. 2) indicated good predictive
performance, with acceptable agreement between prediction- and
variability-corrected observed data and model-simulated confi-
dence intervals for the median and 5th and 95th percentiles.
Parameter estimates for the structural model, interindividual,
TABLE 1 Posaconazole pharmacokinetic data and participant
demographics
Parameter Study 1a Study 2b
Study type Controlled pharmacokinetic
study of posaconazole-
fosamprenavir interaction
Observational study
of posaconazole
TDM
Study population Healthy volunteers Patients treated with
posaconazole
N 20 82
Posaconazole dosing Day 1, 200 mg; day 2, 200 mg
twice a day; days 3–10,
400 mg twice a day
Multiple dosing:
160–1,200 mg
total daily dose
No. of samples/dose
intervalc
11 1
Median age (range),
in yrs
38 (18–54) 50 (18–79)
Median wt (range),
in kg
74 (44–104) 71 (38–122)
Sex [no. (%)]
Female 9 (45) 35 (43)
Male 11 (55) 47 (57)
a Based on data reported in reference 21.
b Based on data reported in reference 6.
c For subjects in study 2, between 1 to 42 samples were measured per patient across
separate dose intervals.
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interoccasion, and residual variability from the base and final
models, and also bootstrap estimates and associated standard er-
rors of the finalmodel, are shown inTable 2. Posaconazole relative
bioavailability after administration as a suspension was found to
be significantly higher in healthy volunteers (study 1) than in pa-
tients receiving posaconazole (study 2). The extent of this effect
was characterized as a relative difference in bioavailability based
on the use of a categorical covariate.
One participant from study 2was initially included in themod-
eling analysis but was found to have an outlying estimate for po-
saconazole volume of distribution. A sensitivity analysis was per-
formed, including reestimation of the base pharmacokinetic
model and stepwise covariate testing procedure, both with and
without this participant included in themodel. As inclusion of this
participant was found to affect the selection of covariates during
forward inclusion and backwards deletion, this participant was
excluded from the analysis.
Effects of covariates onposaconazole pharmacokinetics. Sig-
nificant covariates selected from the stepwise covariate modeling
procedure and included in the final pharmacokinetic model are
shown in Table 3. Concurrent administration of proton pump
inhibitors or metoclopramide was associated with significantly
reduced posaconazole bioavailability, as wasmucositis or diarrhea
on the day of posaconazole concentration sampling, whereas a
concurrent nutritional supplement significantly increased bio-
availability. Concurrent administration of phenytoin, rifampin, or
fosamprenavir was associated with significantly increased apparent
posaconazole clearance. Covariate effects were estimated with good
precision (range of relative standard error, 5.6 to 25.8%). The effects
of these covariates on predicted posaconazole trough concentrations
at steady state are shown in Fig. 3.
Parameter-covariate relationships that were not associated
with a significant effect on posaconazole pharmacokinetics in-
cluded body weight on apparent posaconazole clearance or vol-
FIG 1 Goodness-of-fit plots for the final posaconazole pharmacokinetic model.
Posaconazole Population Pharmacokinetics
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ume of distribution, participant age on apparent posaconazole
clearance, volume of distribution or bioavailability, sex on appar-
ent posaconazole clearance, volume of distribution or bioavail-
ability, ranitidine coadministration on bioavailability, andNGad-
ministration of posaconazole on bioavailability.
DISCUSSION
This study reports an integrated analysis of the population phar-
macokinetics of posaconazole in healthy volunteers and patients
and identifies and quantifies the effects of commonly coadminis-
tered medicines and clinical factors on posaconazole exposure. A
strength of this study is the ability to quantify the significance of
multiple clinical factors that have been reported to influence po-
saconazole pharmacokinetics, using real world data collected
from patients receiving the drug in the clinic.
A one-compartment pharmacokinetic model with first-order
elimination adequately described posaconazole pharmacokinetics
in this study, a finding that was consistent with previous popula-
tion pharmacokinetic studies of posaconazole (24–26). Posacona-
zole exhibits dose-dependent, saturable absorption, with more-
frequent dosing regimens resulting in higher systemic exposures
than do less-frequent dosing regimens, despite an equivalent total
daily dose (3, 4). Krishna et al. reported 2.5-fold higher posacona-
zole exposure among healthy volunteers receiving a posaconazole
suspension at 200 mg four times daily, compared to those receiv-
ing 400 mg twice daily (4). This phenomenon led to the multiple
FIG 2 Prediction- and variability-corrected visual predictive checks of the final model, stratified by study: study 1 (a) and study 2 (b). Prediction- and
variability-corrected observed concentrations are shown as open circles, with the solid and lower and upper dashed lines showing the median and 5th and 95th
percentiles of the observed data, respectively. The shaded areas represent 95% confidence intervals for themodel-predictedmedian and 5th and 95th percentiles
constructed from 1,000 simulated data sets of individuals from the original data set.
TABLE 2 Pharmacokinetic parameter estimates of the base model and
final model and bootstrap estimates of the final model
Parametera
Population estimate
Bootstrap
estimateb
Precision
(RSE)dBase model Final model
Structural model
CL/F (liters/h) 50.8 30.2 30.6 9.9
V/F (liters) 2,090 1,100 1,110 12.8
ka (h
1) 1.33 1.26 1.29 28.4
Absorption lag time (h) 1.79 1.79 1.81 9.2
IIV and IOV
IIV CL/F (% CV) 58.1 46.4 45.8 9.17
IIV V/F (% CV) 73.8 30.2 29.6 32.3
IIV ka (% CV) 46.8 53.4 57 33.4
IOV F (% CV) 28.6 23.6 23.7 13.4
F, volunteers vs patientsc 257% 123% 126% 26.5
Residual variability
Proportional error,
study 1 (% CV)
6.97 6.76 6.77 4.37
Proportional error,
study 2 (% CV)
62.7 53.8 52.8 8.34
a ka, first-order absorption rate constant; CL/F, apparent clearance; V/F, apparent
volume of distribution; F, bioavailability.
b Data obtained from nonparametric bootstrap analysis (200 data sets).
c Difference in bioavailability in healthy volunteers versus patients.
d RSE, relative standard error, expressed as a percentage.
TABLE 3 Significant covariate effects included in the final model
Covariate
Effect on
structural
parametera
Bootstrap
estimate of
effect
Precision
(RSE)b
Effect on relative F
Concurrent proton pump inhibitor 45.1 43.8 11.7
Concurrent metoclopramide 34.5 33.5 21.3
Concurrent nutritional supplement 129 121 16.6
Mucositis 57.7 57.7 5.61
Diarrhea 45.1 38.6 15.5
Effect on CL/F
Concurrent phenytoin/rifampin 621 640 25.8
Concurrent fosamprenavir 34.2 34.3 23.4
a The percent increase or decrease (positive and negative values, respectively); data are
the result of a nonparametric bootstrap analysis (200 data sets).
b RSE, relative standard error, expressed as a percentage.
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daily dose regimens recommended with the current formulation
of posaconazole (3). A saturable absorption model was investi-
gated in this analysis but did not provide an improvement in
model fit, an apparent limitation of this model that is shared with
previous population pharmacokinetic models of posaconazole
(24–26). In this analysis, a single posaconazole dosing regimen
was used in study 1, andwhile a range of dosing regimenswas used
in study 2, concentration sampling was sparse; these factors are
likely to have contributed to the lack of improvement observed
with a saturable absorption model. This relationship has been de-
scribed in the context of short-term administration of the drug to
fasting healthy volunteers (3), and detailed pharmacokinetic data
in patients at a range of posaconazole doses and dose frequencies
would be required to further characterize the relationship be-
tween dose frequency and concentration with posaconazole.
Significantly higher bioavailabilitywas observed in healthy vol-
unteers in this study than in the patients receiving posaconazole
(Table 2; Fig. 3), in agreement with previous reports of higher
exposure in healthy volunteers (27). Healthy volunteers included
in this analysis were administered posaconazole with food (21),
whereas the timing of food consumption in relation to dose was
not known for patients included in this analysis. As food is known
to increase posaconazole exposure by up to 4-fold (4), it is likely
that consistent and concomitant food intake at the time of dosing
at least partially explains the higher bioavailability observed in
healthy volunteers. Furthermore, the significant size of the food
effect observed with posaconazole also explains the increased po-
saconazole bioavailability observed among patients coadminis-
tered a nutritional supplement in this study, supporting the use of
nutritional supplements as an effective strategy to boost po-
saconazole systemic absorption (9, 28).
Coadministration of a proton pump inhibitor and metoclo-
pramidewas associatedwith significantly lower posaconazole bio-
availability in this analysis, confirming the results of previous
crossover studies (4, 5) and clinical observations (19, 29). PPIs
reduce posaconazole solubility as a result of increased pH,with the
dissolved posaconazole concentration in the gastrointestinal lu-
men dictating the extent of posaconazole absorption and, thus,
systemic exposure (5). The prokinetic activity of metoclopramide
is believed to explain its negative effect on posaconazole absorp-
tion (4).
Mucositis, and to a smaller extent diarrhea, were both associ-
ated with reduced posaconazole bioavailability (Table 3; Fig. 3).
Gastrointestinal disorders are common among patients at risk of
IFIs and may be related to chemotherapy, neutropenic enteroco-
litis, or as a symptom of graft-versus-host disease in allogeneic
hematopoietic stem cell transplant recipients (29–31). A relation-
ship between diarrhea on the day of posaconazole blood sampling
and low posaconazole exposure has previously been reported
among two large patient cohorts (29, 30), with a similar relation-
ship described formucositis (32). Asmany patients suffering from
mucositis may be unable to eat, it is probable that a reduction in
food intake with posaconazole contributes to the reduced bio-
availability observed in this study.
Coadministration of fosamprenavir, phenytoin, or rifampin
was associated with an increased apparent clearance of posacona-
zole, with phenytoin or rifampin causing far larger increases in
clearance that were reflected in the very low posaconazole expo-
sure in model simulations with this covariate (Fig. 3). Both phe-
nytoin and rifabutin have been associated with a reduction in the
posaconazole area under the concentration-time curve of approx-
imately 50% in studies of healthy volunteers (33, 34), with a case
study demonstrating a similar interaction with rifampin (35). Ap-
proximately 20 to 30% of a posaconazole dose is known to be
glucuronidated via the phase 2 enzyme UDP-glucuronosyltrans-
ferase 1A4 (UGT1A4) in the liver (36, 37). Both phenytoin and
rifampin are known UGT inducers (38, 39), suggesting that in-
duction of this pathway is the likely mechanism for the increased
posaconazole elimination when these medicines are coadminis-
tered. Taken together, these results suggest that coadministration
of phenytoin or rifampin with posaconazole should be avoided;
frequent monitoring of posaconazole concentration appears pru-
dent if coadministration is deemed necessary.
No relationship between demographic covariates, such as body
FIG 3 Effects of significant covariates on the predicted posaconazole trough concentration on day 10 of therapy following posaconazole at 200 mg three
times daily; data are presented as an adjusted box plot. For each scenario, 1,000 patients or volunteers were simulated with or without the specified
covariate(s). The central box line represents the median trough concentration, the lower and upper box ends represent the 25th and 75th percentiles, and
the bars extend to the 10th and 90th percentiles. The dashed line represents the proposed minimum cutoff concentration for antifungal prophylaxis with
posaconazole (0.7 mg/liter) (9).
Posaconazole Population Pharmacokinetics
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weight, age, or sex, and posaconazole pharmacokinetics was ob-
served in this analysis, in agreement with other analyses of po-
saconazole (24, 27). In contrast with these findings, Kohl et al.
identified an inverse relationship between patient age and the ap-
parent volume of distribution of posaconazole in their analysis of
prophylactic posaconazole use in patients undergoing allogeneic
hematopoietic stem cell transplantation (25), and a relationship
between patient weight and a larger apparent volume of distribu-
tion was observed in a recent population pharmacokinetic analy-
sis of posaconazole (26). As the effects of changes in patient age or
weight on posaconazole exposure were relatively small in these
studies (25, 26), it is possible that differences in covariate testing
methodology and significance criteria between those used in these
studies and those in the present analysis may explain the conflict-
ing results for these covariates.
Coadministration of the H2 receptor antagonist ranitidine did
not significantly affect posaconazole pharmacokinetics. We pre-
viously reported a reduction in posaconazole exposure upon co-
administration of ranitidine in a multiple regression analysis, al-
though this effect was relatively minor compared to proton pump
inhibitor coadministration (regression coefficient, 178 ng/ml
versus 589 ng/ml for PPIs) (6). Vehreschild et al. identified a
significant effect of ranitidine coadministration on the apparent
clearance of posaconazole when ranitidine was included in the
model as a single covariate, but ranitidine was not retained in the
final pharmacokinetic model (26). These results suggest that con-
comitant ranitidine has little or no impact on posaconazole phar-
macokinetics, although a controlled crossover interaction study
would be needed to definitively elucidate the extent of this poten-
tial drug interaction.
In addition, NG administration of posaconazole did not
significantly affect posaconazole pharmacokinetics in this
analysis. A study in healthy volunteers demonstrated a 24%
reduction in posaconazole area under the plasma concentra-
tion-time curve when administered via NG tube (40), with
clinical studies in patients also confirming a significant reduc-
tion in posaconazole exposure (7, 41). The lack of significance
of this covariate in the present study is likely due to the small
number of patients who received posaconazole via NG tube in
this analysis (n  8).
In summary, this study provides an integrated population
pharmacokinetic analysis of posaconazole oral suspension,
demonstrating the impact of a range of drug interactions and
clinical factors that influence posaconazole exposure in pa-
tients. These findings may assist clinicians in identifying factors
that predispose a patient to a suboptimal posaconazole concen-
tration. Furthermore, these findings support the need for ther-
apeutic drug monitoring with posaconazole oral suspension to
ensure adequate systemic exposure, a strategy that is widely
recommended for other azole antifungal agents, such as vori-
conazole (42, 43). While several studies have confirmed that
dose escalation with the posaconazole suspension above a cu-
mulative daily dose of 800 mg does not increase, and may
slightly decrease, posaconazole exposure (31, 44), avoidance of
commonly coadministered medicines, such as PPIs and meto-
clopramide, as well as administration of posaconazole with
food or a nutritional supplement are effective strategies to boost
posaconazole absorption.
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